DGAP-News: Glycotope Biotechnology and Cantargia sign production agreement for lead product candidate CAN04

DGAP-News: Glycotope GmbH / Key word(s): Contract/Miscellaneous
Glycotope Biotechnology and Cantargia sign production agreement for
lead product candidate CAN04

03.07.2015 / 08:49

---------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
TO THE USA, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR
NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS
RELEASE WOULD BE ILLEGAL.

Glycotope Biotechnology and Cantargia sign production agreement for lead
product candidate CAN04

Lund, Sweden and Heidelberg, Germany - July 3, 2015 - Cantargia AB and
Glycotope Biotechnology GmbH today announced an agreement on the production
of Cantargia's proprietary monoclonal antibody CAN04. The product candidate
CAN04 is directed against the target molecule IL1RAP, expressed on cancer
stem cells as well on mature cancer cells. Through the agreement, Glycotope
Biotechnology will be Cantargia's production partner to obtain material for
the clinical studies of CAN04 in cancer patients.

Glycotope Biotechnology will be responsible for the development and the GMP
(Good Manufacturing Practices) production of CAN04. Glycotope Biotechnology
will manufacture the material to be used in both future toxicology studies
and clinical trials.

"The collaboration with Glycotope Biotechnology will be a cornerstone in
the development of CAN04. We look forward to work with Glycotope
Biotechnology", says Göran Forsberg, CEO of Cantargia.

"To bring Cantargia's lead drug candidate into clinical trials will be a
great opportunity for Glycotope Biotechnology as Contract Manufacturer for
innovative biopharmaceuticals", says Franzpeter Bracht, COO of Glycotope
Biotechnology.

About Cantargia

Cantargia AB (reg.no. 556791-6019) is a biotech company that is developing
an antibody-based cancer treatment, which attacks cancer stem cells as well
as mature cancer cells. The original discovery by the research team behind
Cantargia was the overexpression of a specific target molecule, IL1RAP, in
cancer stem cells in patients with leukaemia that is not found in normal
stem cells in the bone marrow. In preclinical studies (in vitro and in
vivo) the antibody, targeted at IL1RAP, has been shown to have two
potential mechanisms of action, which are complementary. The company has
selected a product candidate for future studies in humans. Preclinical
trials with Cantargia's antibodies have shown a potent antileukaemic
effect. Parallel studies have shown an even higher expression of IL1RAP in
certain solid tumors. In 2015 Cantargia will be carrying out the studies
required for authorization of clinical trials.

Sedermera Fondkommission is Cantargias Certified Adviser. 

About Glycotope

Biotechnology Glycotope Biotechnology GmbH is an experienced service
provider for the development and GMP-production of active biopharmaceutical
ingredients, as well as fill and finish and all related services. Currently
Glycotope Biotechnology runs projects from supply for early up to late
clinical trials and for market production of an in vitro diagnostic. The
integrated services cover the supply of clinical trials up to product
launch and market supply. Glycotope Biotechnology supports its clients from
process development & transfer, scale-up, GMP-production including quality,
bioassays and regulatory affairs. The facilities in Heidelberg are designed
for a product range comprising of glycoproteins, antibodies and fusion
proteins in several manufacturing lines up to 1,000 L bioreactors for fed
batch and continuous (perfusion) bioprocesses.

For further information, please contact:

Cantargia AB
Göran Forsberg, CEO
Phone.: +46 (0)46-275 62 60
Email: goran.forsberg@cantargia.com

Glycotope GmbH
Dr. Franzpeter Bracht, COO
Phone.: +49 (0) 6221 91050
Email: franzpeter.bracht@glycotope.com
Website: www.glycotope.com



---------------------------------------------------------------------

03.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


374921 03.07.2015